Literature DB >> 19268434

Levetiracetam enhances endogenous antioxidant in the hippocampus of rats: in vivo evaluation by brain microdialysis combined with ESR spectroscopy.

Yuto Ueda1, Taku Doi, Mayuko Takaki, Keiko Nagatomo, Akira Nakajima, L James Willmore.   

Abstract

We have attempted to explore the neuroprotective effectiveness of levetiracetam (LEV) by measuring its in vivo antioxidant effect in the hippocampus of rats in a freely moving state. Male Wistar rats were used for the estimation of the in vivo antioxidant effect of LEV through microdialysis combined with electron spin resonance spectroscopy. The antioxidant effect was examined using the principle by which a systemically administered blood-brain barrier-permeable nitroxide radical (PCAM) decreases in an exponential decay manner that is correlated with the amount of antioxidant in the brain. The PCAM decay ratio during perfusion with normal Ringer's solution was compared with that during 32 microM and 100 microM LEV co-perfusion. The in vivo antioxidant effect was examined. In addition, the expressions of the cystine/glutamate exchanger (xCT) and the inducible nitric oxide synthase (iNOS) protein related to redox regulation were measured in the hippocampus of rats after 14 days of administration of LEV at a dose of 54 mg/day i.p. The half-life of PCAM was statistically shortened after LEV perfusion compared with the results of the control experiment. While the expression of the pro-oxidant protein iNOS was decreased, that of the antioxidant protein xCT was statistically increased by the administration of LEV. The role of xCT is to transport cystine, the internal material of glutathione, into the cell. The shortened half-life of the nitroxide radical by co-perfusion of LEV with increased xCT and decreased iNOS expression revealed the enhancement of the endogenous antioxidant effect or free-radical scavenging activity. The results of this study suggest that LEV synergistically enhances the basal endogenous antioxidant effect in the hippocampus with ascorbic acid and alpha-tocopherol. Our findings further suggest that LEV exerts a neuroprotective role by 1) modifying the expression of xCT and iNOS in connection with lipid peroxidation, 2) synergistically enhancing the increased basal endogenous antioxidant ability in the hippocampus, and 3) decreasing the basal concentration of glutamate followed by up-regulation of the intake of cystine, an internal material of GSH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19268434     DOI: 10.1016/j.brainres.2009.02.040

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

Review 1.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Authors:  Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2012-08-03       Impact factor: 8.401

2.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

Authors:  George C Bobustuc; Cheryl H Baker; Arati Limaye; Wayne D Jenkins; Gary Pearl; Nicholas G Avgeropoulos; Santhi D Konduri
Journal:  Neuro Oncol       Date:  2010-06-04       Impact factor: 12.300

3.  The Antiepileptic Drug Levetiracetam Protects Against Quinolinic Acid-Induced Toxicity in the Rat Striatum.

Authors:  Maricela Dircio-Bautista; Ana Laura Colín-González; Gabriela Aguilera; Marisol Maya-López; Juana Villeda-Hernández; Sonia Galván-Arzate; Esperanza García; Isaac Túnez; Abel Santamaría
Journal:  Neurotox Res       Date:  2017-11-09       Impact factor: 3.911

Review 4.  Analytical and biological methods for probing the blood-brain barrier.

Authors:  Courtney D Kuhnline Sloan; Pradyot Nandi; Thomas H Linz; Jane V Aldrich; Kenneth L Audus; Susan M Lunte
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2012       Impact factor: 10.745

5.  Hydrogen-related enhancement of in vivo antioxidant ability in the brain of rats fed coral calcium hydride.

Authors:  Yuto Ueda; Akira Nakajima; Taneaki Oikawa
Journal:  Neurochem Res       Date:  2010-07-22       Impact factor: 3.996

6.  Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats.

Authors:  Mustafa Komur; Cetin Okuyaz; Yalcin Celik; Bora Resitoglu; Ayse Polat; Senay Balci; Lulufer Tamer; Semra Erdogan; Huseyin Beydagi
Journal:  Childs Nerv Syst       Date:  2014-02-14       Impact factor: 1.475

7.  Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes.

Authors:  Sara Sanz-Blasco; Juan C Piña-Crespo; Xiaofei Zhang; Scott R McKercher; Stuart A Lipton
Journal:  Neuroreport       Date:  2016-06-15       Impact factor: 1.837

8.  Enhancement of in vivo antioxidant ability in the brain of rats fed tannin.

Authors:  Akira Nakajima; Yuto Ueda; Emiko Matsuda; Hiroshi Sameshima; Tsuyomu Ikenoue
Journal:  Neurochem Res       Date:  2013-04-04       Impact factor: 3.996

Review 9.  The role of levetiracetam in treatment of seizures in brain tumor patients.

Authors:  Ekokobe Fonkem; Paul Bricker; Diana Mungall; Jose Aceves; Eromata Ebwe; Wei Tang; Batool Kirmani
Journal:  Front Neurol       Date:  2013-10-07       Impact factor: 4.003

10.  The strategy for enhancing temozolomide against malignant glioma.

Authors:  Mitsutoshi Nakada; Takuya Furuta; Yutaka Hayashi; Toshinari Minamoto; Jun-Ichiro Hamada
Journal:  Front Oncol       Date:  2012-08-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.